ID24240A - Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p - Google Patents

Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p

Info

Publication number
ID24240A
ID24240A IDW20000926A ID20000926A ID24240A ID 24240 A ID24240 A ID 24240A ID W20000926 A IDW20000926 A ID W20000926A ID 20000926 A ID20000926 A ID 20000926A ID 24240 A ID24240 A ID 24240A
Authority
ID
Indonesia
Prior art keywords
piperidinylaminomethy
antagonic
trifloromethyl
eter
cycle
Prior art date
Application number
IDW20000926A
Other languages
English (en)
Indonesian (id)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID24240A publication Critical patent/ID24240A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20000926A 1997-11-19 1998-10-26 Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p ID24240A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19

Publications (1)

Publication Number Publication Date
ID24240A true ID24240A (id) 2000-07-13

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000926A ID24240A (id) 1997-11-19 1998-10-26 Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p

Country Status (39)

Country Link
US (2) US20030208079A1 (fr)
EP (1) EP1032571B1 (fr)
JP (2) JP3394239B2 (fr)
KR (1) KR100366902B1 (fr)
CN (1) CN1173974C (fr)
AP (1) AP909A (fr)
AR (1) AR016422A1 (fr)
AT (1) ATE219078T1 (fr)
AU (1) AU734218B2 (fr)
BG (1) BG63969B1 (fr)
CA (1) CA2310627C (fr)
CO (1) CO4771153A1 (fr)
CZ (1) CZ297315B6 (fr)
DE (1) DE69806045T2 (fr)
DK (1) DK1032571T3 (fr)
DZ (1) DZ2655A1 (fr)
EA (1) EA002621B1 (fr)
ES (1) ES2177058T3 (fr)
HR (1) HRP20000313B1 (fr)
HU (1) HUP0101112A3 (fr)
ID (1) ID24240A (fr)
IL (1) IL135631A0 (fr)
IS (1) IS2202B (fr)
MA (1) MA26567A1 (fr)
MY (1) MY120558A (fr)
NO (2) NO20002544L (fr)
NZ (1) NZ503912A (fr)
OA (1) OA11380A (fr)
PA (1) PA8463001A1 (fr)
PE (1) PE20000021A1 (fr)
PL (1) PL193484B1 (fr)
PT (1) PT1032571E (fr)
RS (1) RS49792B (fr)
SK (1) SK283460B6 (fr)
TN (1) TNSN98210A1 (fr)
TR (1) TR200001463T2 (fr)
TW (1) TW426667B (fr)
UA (1) UA59417C2 (fr)
WO (1) WO1999025714A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
AU3572800A (en) * 1999-05-06 2000-11-21 Pfizer Products Inc. Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
WO2000071538A2 (fr) * 1999-05-21 2000-11-30 Pfizer Products Inc. Derives 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchromane
AU7557000A (en) * 1999-10-07 2001-05-10 Hisamitsu Pharmaceutical Co. Inc. Piperidine derivatives
ATE257477T1 (de) * 1999-10-18 2004-01-15 Pfizer Prod Inc Verfahren zur herstellung von zyklischen piperidinylaminomethyl-trifluoromethyl- etherderivaten
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP1288208B1 (fr) 2001-08-30 2006-07-12 Pfizer Products Inc. Procedure pour la Preparation du 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyde et derivés du -Benzylidenyl par substitution nucleophilic aromatic du 2-Fluorobenzaldehyde avec le 4-Alkyl-1-Piperazine et de l'eau comme solvant
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
WO2004019865A2 (fr) * 2002-08-27 2004-03-11 Witten Mark L Amelioration des effets de la fumee de cigarette
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
EP4117673A1 (fr) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Traitement d'une déficience en cellules souches

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
US5886011A (en) * 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
ATE199552T1 (de) * 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
WO2000071538A2 (fr) * 1999-05-21 2000-11-30 Pfizer Products Inc. Derives 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchromane
ATE257477T1 (de) * 1999-10-18 2004-01-15 Pfizer Prod Inc Verfahren zur herstellung von zyklischen piperidinylaminomethyl-trifluoromethyl- etherderivaten

Also Published As

Publication number Publication date
BG104437A (en) 2001-02-28
PA8463001A1 (es) 2000-09-29
DZ2655A1 (fr) 2003-03-22
PE20000021A1 (es) 2000-02-25
US20050171354A1 (en) 2005-08-04
DE69806045D1 (en) 2002-07-18
ES2177058T3 (es) 2002-12-01
CN1173974C (zh) 2004-11-03
RS49792B (sr) 2008-06-05
AP909A (en) 2000-12-04
SK7232000A3 (en) 2001-09-11
DE69806045T2 (de) 2002-11-14
NZ503912A (en) 2002-09-27
JP2001523680A (ja) 2001-11-27
US20030208079A1 (en) 2003-11-06
AU9454998A (en) 1999-06-07
HRP20000313B1 (en) 2002-04-30
KR100366902B1 (ko) 2003-01-09
CN1279681A (zh) 2001-01-10
JP2003040777A (ja) 2003-02-13
AU734218B2 (en) 2001-06-07
SK283460B6 (sk) 2003-08-05
PL193484B1 (pl) 2007-02-28
YU29400A (sh) 2003-02-28
UA59417C2 (uk) 2003-09-15
DK1032571T3 (da) 2002-07-15
AP9801402A0 (en) 1998-12-31
PT1032571E (pt) 2002-09-30
MA26567A1 (fr) 2004-12-20
EA200000432A1 (ru) 2000-12-25
NO20002544L (no) 2000-07-17
CZ20001834A3 (cs) 2001-07-11
HUP0101112A3 (en) 2002-06-28
AR016422A1 (es) 2001-07-04
NO20042879L (no) 2000-07-17
CA2310627A1 (fr) 1999-05-27
HUP0101112A2 (hu) 2002-05-29
IS2202B (is) 2007-02-15
ATE219078T1 (de) 2002-06-15
CO4771153A1 (es) 1999-04-30
WO1999025714A1 (fr) 1999-05-27
EA002621B1 (ru) 2002-06-27
JP3394239B2 (ja) 2003-04-07
TW426667B (en) 2001-03-21
OA11380A (en) 2004-01-27
TR200001463T2 (tr) 2000-12-21
MY120558A (en) 2005-11-30
EP1032571A1 (fr) 2000-09-06
TNSN98210A1 (fr) 2005-03-15
IL135631A0 (en) 2001-05-20
IS5470A (is) 2000-04-26
PL340642A1 (en) 2001-02-12
CA2310627C (fr) 2005-08-09
BG63969B1 (bg) 2003-08-29
HK1033313A1 (en) 2001-08-24
EP1032571B1 (fr) 2002-06-12
HRP20000313A2 (en) 2000-12-31
CZ297315B6 (cs) 2006-11-15
NO20002544D0 (no) 2000-05-18

Similar Documents

Publication Publication Date Title
ID24240A (id) Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
FI960156A7 (fi) Bentsyylioksikinuklidiinit aineet P antagonisteina
MA24035A1 (fr) Formulations injectables de quinolones
EE200000321A (et) Uudsed ühendid
ID26102A (id) Proses pembuatan senyawa-senyawa stilbena
NO20001728D0 (no) Fremgangsmåte for fremstilling av chirale forbindelser
ID22641A (id) Proses pembuatan e-kaprolaktam
ID19754A (id) Metode untuk memproduksi formal siklik secara kontinyu
NO20004288D0 (no) FremgangsmÕte til fremstilling av et beskyttet 4-aminometyl- pyrrolidin-3-on
ID22840A (id) Proses untuk penyiapan komposisi aspal
NO20023937L (no) Fremgangsmåte for fremstilling av substituert tiazolidindion
DE69601899D1 (de) Zementzusammensetzung
ID24527A (id) Proses pembuatan senyawa-senyawa farmasi
NO20001777L (no) Fremgangsmate for fremstilling av substituerte 4-fenyl-4-cyanocykloheksankarboksylsyrer
ID24327A (id) Produksi senyawa-senyawa avermektin
FI973111A7 (fi) Substituoidut fenyyliyhdisteet endoteliiniantagonisteina
NO996432D0 (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
ID22430A (id) Proses pembuatan senyawa-senyawa benzotiazolona
ID23410A (id) Senyawa-senyawa amonium kuaterner sebagai antagonis tacikinin
ATE289195T1 (de) Verwendung von substituierten 4-amino-1- phenylbutan-2-ol-verbindungen als arzneimittel
ID19763A (id) Proses produksi bahan organik butiran
NO20030587L (no) Fremgangsmåte til fremstilling av diskodermolid og analoger derav
NO20003077L (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner